Laminine Testimonials stroke Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For More Info About Laminine, How a... By: Karl Angelo Alipin … Continue reading →

Laminine Testimonial-kidney failure Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For More Info About Laminine, How a... By: Karl Angelo Alipin … Continue reading →

Stem cell treatment of Cartilage injuries India Cartilage injuries of the knee are prevalent in the young population. They result from sports injuries, knee deformities, accidents etc. Here Stem cell treat... By: ALAMPALLAM VENKATACHALAM … Continue reading →

Albany, NY (PRWEB) September 15, 2014 Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc.. View Full Report at http://www.marketresearchreports.biz/analysis/223134 Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/223134 The stem cell technology and product research-oriented midstream sector is in its … Continue reading →

PUBLIC RELEASE DATE: 13-Sep-2014 Contact: Philly Lim mllim@wspc.com 656-466-5775 World Scientific @worldscientific 65 million people around the world today suffer from epilepsy, a condition of the brain that may trigger an uncontrollable seizure at any time, often for no known reason. A seizure is a disruption of the electrical communication between neurons, and someone is said to have epilepsy if they experience two or more unprovoked seizures separated by at least 24 hours. Epilepsy is the most common chronic disease in pediatric neurology, with about 0.5% of children developing epilepsy during their lifetime. A further 30% of epileptic children develop refractory epilepsy, a particular type of epilepsy that cannot be managed by antiepileptic drugs (AED). Regardless of etiology, children with refractory epilepsy are invariably exposed to a variety of physical, psychological and social morbidities. Patients whose seizures are difficult to control could benefit from non-pharmacological therapies, including surgery, deep brain stimulation and ketogenic diets. Therefore, the early identification of patients whose seizures are refractory to AED would allow them to receive alternative therapies at an appropriate time. Despite idiopathic etiology being a significant predictor of a lower risk of refractory epilepsy, a subset of patients with idiopathic epilepsy might still … Continue reading →

Greenbelt, MD (PRWEB) September 15, 2014 With a simple swab of the cheek, the physicians at Center for Vascular Medicine can gain valuable insight to help personalize the treatment for patients with vascular disorders, including peripheral artery disease (PAD). The ideal approach to medicine is preventive care. But, it can be difficult for a doctor to predict how a patient will respond to specific drugs. A simple cheek swab test can be used to identify a patients genetic makeup, allowing the physician to tailor medical therapy and optimize outcomes. By tailoring the dose and regimen of pharmaceutical treatment to the patients genetics, we are able to deliver more effective therapy and avoid unwanted side effects, says Sanjiv Lakhanpal MD, founder of the Center for Vascular Medicine. The mapping of the human genome in 2003 gave researchers insight into Cytochrome P450 (CYP450), a group of enzymes that are involved in drug metabolism. The test creates a road map for the individual to enable the physician to predict the effectiveness of certain drugs. For example, blood thinners which are commonly prescribed to patients with vascular conditions. Many adults in the United States routinely take five or more prescription medications. This is particularly … Continue reading →

PUBLIC RELEASE DATE: 14-Sep-2014 Contact: Leslie Ridgeway lridgewa@usc.edu University of Southern California - Health Sciences An international study co-led by Keck School of Medicine of the University of Southern California (USC) scientists and researchers in the United Kingdom has revealed 23 new genetic susceptibility locations indicating risk for prostate cancer. The data study, analyzing more than 87,000 individuals of European, African, Japanese and Latino ancestry, is the largest of its kind and is the first that combines multiple studies across different ethnic populations. "The goal of this research is to identify regions of the genome that contribute susceptibility to prostate cancer that could be used for understanding a man's future risk of developing this disease," said principal investigator Christopher Haiman, Sc.D., professor of preventive medicine, Keck School of Medicine of USC. "This research also emphasizes the importance of common genetic variation in the etiology of prostate cancer, and the importance of large-scale international genetics consortia." According to the American Cancer Society, prostate cancer is the second most common cancer among American men, behind skin cancer. It is estimated that nearly 30,000 men will die of prostate cancer and more than 233,000 new cases will be diagnosed in 2014. Past genome-wide … Continue reading →